BACKGROUND: Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. METHODS: We followed a large cohort of patients seen in 1 of 11 HIV clinics in the United Kingdom after starting cART with nucleoside reverse-transcriptase inhibitors and either a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Survival analysis was employed to estimate the incidence of virological failure and of detected drug resistance. RESULTS: Seven thousand eight hundred ninety-one patients were included; 6448 (82%) started cART with an NNRTI and 1423 (17%) with a PI/r. The cumulative risk of virological failure by 8 years was 28%. The cumulative probabilities of detecting any mutation, > or =1 major nucleoside reverse-transcriptase inhibitor International AIDS Society-United States of America (IAS-USA) mutation, > or =1 major NNRTI IAS-USA mutation (in those starting an NNRTI), and > or =1 major PI IAS-USA mutation (in those starting a PI) were 17%, 14%, 15%, and 7%, respectively, by 8 years. The probability of detecting PI mutations in people who started PI/r-based regimens was lower than that of detecting NNRTI mutations in those starting NNRTI-based regimens (adjusted relative hazard, 0.36; 95% confidence interval, 0.26-0.50; P<.001). The risk of detecting nucleoside resistance did not vary according to whether an NNRTI or a PI/r was used in the regimen (adjusted relative hazard, 1.00; 95% confidence interval, 0.80-1.26; P=.98). CONCLUSIONS: In patients who started modern cART in clinical practice in the United Kingdom, virological failure by 8 years was relatively common and was paralleled by an appreciable risk of resistance detection, although the detection rate of class-specific resistance was lower for those who started a PI/r-based regimen.
BACKGROUND: Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infectedpatients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. METHODS: We followed a large cohort of patients seen in 1 of 11 HIV clinics in the United Kingdom after starting cART with nucleoside reverse-transcriptase inhibitors and either a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Survival analysis was employed to estimate the incidence of virological failure and of detected drug resistance. RESULTS: Seven thousand eight hundred ninety-one patients were included; 6448 (82%) started cART with an NNRTI and 1423 (17%) with a PI/r. The cumulative risk of virological failure by 8 years was 28%. The cumulative probabilities of detecting any mutation, > or =1 major nucleoside reverse-transcriptase inhibitor International AIDS Society-United States of America (IAS-USA) mutation, > or =1 major NNRTI IAS-USA mutation (in those starting an NNRTI), and > or =1 major PI IAS-USA mutation (in those starting a PI) were 17%, 14%, 15%, and 7%, respectively, by 8 years. The probability of detecting PI mutations in people who started PI/r-based regimens was lower than that of detecting NNRTI mutations in those starting NNRTI-based regimens (adjusted relative hazard, 0.36; 95% confidence interval, 0.26-0.50; P<.001). The risk of detecting nucleoside resistance did not vary according to whether an NNRTI or a PI/r was used in the regimen (adjusted relative hazard, 1.00; 95% confidence interval, 0.80-1.26; P=.98). CONCLUSIONS: In patients who started modern cART in clinical practice in the United Kingdom, virological failure by 8 years was relatively common and was paralleled by an appreciable risk of resistance detection, although the detection rate of class-specific resistance was lower for those who started a PI/r-based regimen.
Authors: Stefany Moreno-Gamez; Alison L Hill; Daniel I S Rosenbloom; Dmitri A Petrov; Martin A Nowak; Pleuni S Pennings Journal: Proc Natl Acad Sci U S A Date: 2015-05-18 Impact factor: 11.205
Authors: Steven Y Hong; Jean B Nachega; Karen Kelley; Silvia Bertagnolio; Vincent C Marconi; Michael R Jordan Journal: Infect Disord Drug Targets Date: 2011-04
Authors: Tengiz Tsertsvadze; Nikoloz Chkhartishvili; Lali Sharvadze; Natia Dvali; Otar Chokoshvili; Pati Gabunia; Akaki Abutidze; Kenrad Nelson; Jack Dehovitz; Carlos Del Rio Journal: AIDS Res Treat Date: 2011-02-21
Authors: Karin J Metzner; Christine Leemann; Francesca Di Giallonardo; Christina Grube; Alexandra U Scherrer; Dominique Braun; Herbert Kuster; Rainer Weber; Huldrych F Guenthard Journal: PLoS One Date: 2011-07-06 Impact factor: 3.240
Authors: Mattia C F Prosperi; Simona Di Giambenedetto; Iuri Fanti; Genny Meini; Bianca Bruzzone; Annapaola Callegaro; Giovanni Penco; Patrizia Bagnarelli; Valeria Micheli; Elisabetta Paolini; Antonio Di Biagio; Valeria Ghisetti; Massimo Di Pietro; Maurizio Zazzi; Andrea De Luca Journal: BMC Med Inform Decis Mak Date: 2011-06-14 Impact factor: 2.796
Authors: Sara Lodi; Huldrych F Günthard; David Dunn; Federico Garcia; Roger Logan; Sophie Jose; Heiner C Bucher; Alexandra U Scherrer; Marie-Paule Schneider; Matthias Egger; Tracy R Glass; Peter Reiss; Ard van Sighem; T Sonia Boender; Andrew N Phillips; Kholoud Porter; David Hawkins; Santiago Moreno; Susana Monge; Dimitrios Paraskevis; Metallidis Simeon; Georgia Vourli; Caroline Sabin; Miguel A Hernán Journal: AIDS Date: 2018-01-28 Impact factor: 4.177